Latest News
Organization of African First Ladies for Development Signs Agreement with Sabin Vaccine Institute to Develop Cervical Cancer Elimination Strategy
The Organization of African First Ladies for Development (OAFLAD) and Sabin Vaccine Institute, on behalf of the Global HPV Consortium, have entered into a three-year agreement to advance action towards HPV prevention and cervical cancer elimination on the African continent. This was an agreement as a result of the decision of the highest decision-making organ of the OAFLAD which is […]
Read moreOrganisation des Premières Dames d’Afrique pour le Développement (OPDAD) Symposium stratégique pour définir la vision 2025-2030 de l’OPDAD
Addis-Abeba, Éthiopie – 2 au 3 décembre 2024: L’Organisation des Premières Dames d’Afrique pour le Développement (OPDAD) organisera un symposium stratégique sur le thème « Façonner la vision 2025-2030 : Relever les défis du développement pour faire progresser l’égalité entre les hommes et les femmes » au siège de la Commission de l’Union africaine à Addis-Abeba. Cette rencontre cruciale a […]
Read moreOrganization of African First Ladies for Development (OAFLAD) Strategic Symposium to Shape OAFLAD’s 2025-2030 Vision
Addis Ababa, Ethiopia – December 2-3, 2024: The Organization of African First Ladies for Development (OAFLAD) will host a Strategic Symposium under the theme “Shaping the 2025-2030 Vision: Addressing Developmental Challenges to Advance Gender Equality” at the African Union Commission headquarters in Addis Ababa. This pivotal gathering aims to reflect on OAFLAD’s journey, analyze pressing developmental challenges, and define strategic […]
Read moreAbout Us
General assembly theme of the year 2024
Educate Her and Transform Africa:
Enhancing access to health and education for the 21st century's African Women and girls
Our Partners
The Organization of African First Ladies for Development partners with like-minded organizations in order to promote collaborative work and encourage stakeholders’ commitment to development programs.